Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza(®), Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treat...

詳細記述

保存先:
書誌詳細
出版年:Pharmacoeconomics
主要な著者: Büyükkaramikli, Nasuh C., Blommestein, Hedwig M., Riemsma, Rob, Armstrong, Nigel, Clay, Fiona. J., Ross, Janine, Worthy, Gill, Severens, Johan, Kleijnen, Jos, Al, Maiwenn J.
フォーマット: Artigo
言語:Inglês
出版事項: Springer International Publishing 2017
主題:
Review Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684255/
https://ncbi.nlm.nih.gov/pubmed/28656543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0528-y
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料